Latest News and Press Releases

Q3 Cash Balance of $113.6M – Cash through Q3 2019 Continued progress on the advancement of key clinical programs including GITRL-Fc Phase 1 initiation Management to Host Conference Call/Webcast this...

REDWOOD CITY, Calif., Oct. 24, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...

REDWOOD CITY, Calif., Sept. 19, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...

REDWOOD CITY, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...

Wholly-owned Immuno-oncology Candidate GITRL-Fc to enter clinic in 2H 2017 Q2 Cash Balance of $129.8M – Cash Through Q3 2019 Management to Host Conference Call/Webcast this afternoon at 4:30 p.m. ET...

REDWOOD CITY, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...

Q1 Cash Balance of $156.9M – Cash Through Q3 2019 Phase 2 Demcizumab DENALI Non-Small Cell Lung Cancer Trial Did Not Meet Endpoints Focused on Immuno-Oncology Pipeline and Celgene Collaboration...

REDWOOD CITY, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer...

REDWOOD CITY, Calif., May 03, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer...

REDWOOD CITY, Calif., April 24, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...